Patent ID: 11884725
Assignee: AMPSOURCE BIOPHARMA SHANGHAI INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 0:
1. An antibody or an antigen-binding fragment thereof capable of specifically binding to TIM-3, comprising complementarity determining regions (CDRs) selected from following groups:
(a) following three CDRs of a heavy chain variable region (VH):
(i) CDR-H1, which has a sequence of CDR-H1 contained in a VH as shown by SEQ ID NO: 1, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-H1 contained in the VH;
(ii) CDR-H2, which has a sequence of CDR-H2 contained in the VH as shown by SEQ ID NO: 1, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-H2 contained in the VH; and
(iii) CDR-H3, which has a sequence of CDR-H3 contained in the VH as shown by SEQ ID NO: 1, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-H3 contained in the VH; and/or
following three CDRs of a light chain variable region (VL):
(iv) CDR-L1, which has a sequence of CDR-L1 contained in a VL as shown by SEQ ID NO: 2, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-L1 contained in the VL;
(v) CDR-L2, which has a sequence of CDR-L2 contained in the VL as shown by SEQ ID NO: 2, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-L2 contained in the VL; and
(vi) CDR-L3, which has a sequence of CDR-L3 contained in the VL as shown by SEQ ID NO: 2, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-L3 contained in the VL; or
(b) following three CDRs of a heavy chain variable region (VH):
(i) CDR-H1, which has a sequence of CDR-H1 contained in a VH as shown by SEQ ID NO: 7, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-H1 contained in the VH;
(ii) CDR-H2, which has a sequence of CDR-H2 contained in the VH as shown by SEQ ID NO: 7, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-H2 contained in the VH; and
(iii) CDR-H3, which has a sequence of CDR-H3 contained in the VH as shown by SEQ ID NO: 7, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-H3 contained in the VH; and/or
following three CDRs of a light chain variable region (VL):
(iv) CDR-L1, which has a sequence of CDR-L1 contained in a VL as shown by SEQ ID NO: 8, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-L1 contained in the VL;
(v) CDR-L2, which has a sequence of CDR-L2 contained in the VL as shown by SEQ ID NO: 8, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-L2 contained in the VL; and
(vi) CDR-L3, which has a sequence of CDR-L3 contained in the VL as shown by SEQ ID NO: 8, or has a sequence with one or more substitutions, deletions or additions relative to the sequence of CDR-L3 contained in the VL;
wherein, the substitutions in any one of (i) to (vi) are conservative substitutions;
wherein, CDR-H1, CDR-H2 and CDR-H3 contained in the heavy chain variable region (VH), and/or CDR-L1, CDR-L2 and CDR-L3 contained in the light chain variable region (VL) are defined by a Kabat, Chothia or IMGT numbering system.